Working… Menu

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00303940
Recruitment Status : Completed
First Posted : March 17, 2006
Last Update Posted : March 15, 2012
National Cancer Institute (NCI)
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:

RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving talabostat together with temozolomide or carboplatin may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of talabostat when given together with temozolomide or carboplatin in treating young patients with relapsed or refractory brain tumors or other solid tumors.

Condition or disease Intervention/treatment Phase
Brain and Central Nervous System Tumors Childhood Germ Cell Tumor Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Sarcoma Unspecified Childhood Solid Tumor, Protocol Specific Drug: carboplatin Drug: talabostat mesylate Drug: temozolomide Other: pharmacological study Phase 1

Detailed Description:



  • Determine the dose of talabostat, when used in combination with either temozolomide or carboplatin, at which maximum plasma dipeptidyl peptidase IV enzyme inhibition is achieved (in the absence of talabostat-related dose-limiting toxicity) in pediatric patients with refractory or relapsed solid tumors, including brain tumors.
  • Determine the maximum tolerated dose of talabostat, when used in combination with temozolomide or carboplatin in pediatric patients, if dose-limiting toxicity attributed to talabostat is observed.
  • Define the toxicity profile of talabostat when used in combination with temozolomide or carboplatin.
  • Describe the pharmacokinetic profile of talabostat in pediatric patients.


  • Study levels, at baseline and after drug administration, of serum cytokines (interleukin [IL]-2, IL-6, IL-10, filgrastim [G-CSF], tumor necrosis factor-α, IL-1β, IL-8, IP10, and thrombospondin) that may be important in the immune-mediated antitumor effect of talabostat.
  • Evaluate the antitumor effect of talabostat in combination with temozolomide or carboplatin on pediatric solid tumors by direct assessment of tumor response.
  • Study the effect of talabostat on neutrophil function.
  • Evaluate the expression of fibroblast activation protein (FAP) in pediatric tumors using immunohistochemistry to detect FAP in paraffin-embedded tissue sections from existing tumor specimens, when available.

OUTLINE: This is a dose-escalation study of talabostat. Patients are stratified according to tumor histology and prior therapy.

Based on stratification, patients receive either oral temozolomide on days 1-5 or carboplatin IV over 30 minutes on days 1-2. Patients also receive oral talabostat on days 7-20. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 5/25/2009)

Cohorts of 2-6 patients receive escalating doses of talabostat until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or < 4 of 12 patients experience dose-limiting toxicity during the first course of therapy.

PROJECTED ACCRUAL: A total of 26 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 26 participants
Primary Purpose: Treatment
Official Title: A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors
Study Start Date : December 2005
Actual Study Completion Date : February 2010

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed solid tumors, including, but not limited to, any of the following:

    • Rhabdomyosarcoma and other soft tissue sarcomas
    • Ewing's sarcoma family of tumors
    • Osteosarcoma
    • Neuroblastoma
    • Wilms' tumor
    • Hepatic tumors
    • Germ cell tumors
    • Primary brain tumors

      • In patients with brainstem or optic gliomas, requirement for histological confirmation can be waived if biopsy was not performed

        • Patients with brainstem gliomas that did not respond to therapy but that are without radiographic evidence of disease progression must have clinical evidence of progression
      • Patients with brain tumors must be on stable or tapering dose of corticosteroids for 7 days prior to study entry
  • Measurable or evaluable disease
  • Relapsed or failed to respond to frontline curative therapy, including any of the following:

    • Surgery
    • Radiotherapy
    • Chemotherapy
    • Combination of modalities
  • No other potentially curative treatment options available


  • ECOG performance status 0-2
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Hemoglobin ≥ 8 mg/dL
  • Platelet count ≥ 100,000/mm^3 (platelet transfusion independent)
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • SGPT ≤ 2.5 times ULN
  • Creatinine clearance ≥ 60 mL/min OR age-adjusted creatinine* as follows:

    • No more than 0.8 mg/dL (for patients ≤ 5 years of age)
    • No more than 1.0 mg/dL (for patients 6 to 10 years of age)
    • No more than 1.2 mg/dL (for patients 11 to 15 years of age)
    • No more than 1.5 mg/dL (for patients > 15 years of age) NOTE: *For patients receiving carboplatin a nuclear glomerular filtration rate study, 24-hour urine collection, and serum creatinine for estimation of creatinine clearance is required if under 15 years of age OR serum creatinine and weight for estimation of creatinine clearance is required if 15-18 years of age
  • Patients with history of seizures eligible if seizures controlled by anticonvulsants
  • No clinically significant, unrelated systemic illness, including either of the following:

    • Serious infections
    • Hepatic, renal, or other organ dysfunction that would preclude study treatment
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No generalized pitting peripheral edema
  • No sensitivity to valine-proline boronic acid


  • See Disease Characteristics
  • Recovered to ≤ grade 1 from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study entry
  • Any number of prior chemotherapy regimens allowed
  • Prior temozolomide or carboplatin as frontline therapy or in the adjuvant setting allowed provided patient did not experience severe toxicities related to the drug and tumor progressed during this therapy
  • At least 3 weeks since last dose of all myelosuppressive chemotherapy
  • At least 7 days since last dose of anticancer biologic agents (e.g., retinoids)
  • At least 30 days since prior investigational agents
  • At least 4 weeks since prior radiotherapy to > 25% of marrow-containing bones (pelvis, spine, or skull) (2 weeks for palliative [limited-port] radiotherapy)
  • At least 2 months since prior autologous stem cell transplantation and recovered
  • At least 1 week since prior filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa
  • At least 2 weeks since prior pegfilgrastim
  • No history of allogeneic stem cell transplantation
  • No other concurrent anticancer chemotherapy, radiation therapy, or immunotherapy
  • No other concurrent investigational agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00303940

Layout table for location information
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Holly Meany, MD National Cancer Institute (NCI)
Principal Investigator: Elizabeth Fox, MD National Cancer Institute (NCI)

Publications of Results:
Layout table for additonal information Identifier: NCT00303940     History of Changes
Obsolete Identifiers: NCT00261885
Other Study ID Numbers: 050239
First Posted: March 17, 2006    Key Record Dates
Last Update Posted: March 15, 2012
Last Verified: March 2012
Keywords provided by National Institutes of Health Clinical Center (CC):
unspecified childhood solid tumor, protocol specific
recurrent childhood rhabdomyosarcoma
recurrent childhood soft tissue sarcoma
recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
recurrent osteosarcoma
recurrent neuroblastoma
recurrent Wilms tumor and other childhood kidney tumors
recurrent childhood malignant germ cell tumor
recurrent childhood liver cancer
recurrent childhood brain stem glioma
recurrent childhood cerebellar astrocytoma
recurrent childhood cerebral astrocytoma
recurrent childhood ependymoma
recurrent childhood medulloblastoma
recurrent childhood supratentorial primitive neuroectodermal tumor
childhood atypical teratoid/rhabdoid tumor
childhood low-grade cerebral astrocytoma
childhood high-grade cerebral astrocytoma
childhood choroid plexus tumor
childhood craniopharyngioma
childhood infratentorial ependymoma
childhood supratentorial ependymoma
childhood oligodendroglioma
recurrent childhood visual pathway and hypothalamic glioma
recurrent childhood brain tumor
childhood central nervous system germ cell tumor
childhood grade I meningioma
childhood grade II meningioma
childhood grade III meningioma
childhood malignant ovarian germ cell tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Neoplasms
Liver Neoplasms
Neoplasms, Germ Cell and Embryonal
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Digestive System Neoplasms
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action